Patents
Polypeptide having an activity to support proliferation or survival of hematopoietic stem or progenitor cells
Patent Number: 7,439,332This patent covers a specific nucleic acid sequence and expressed protein thereof, for the stimulation of erythropoiesis. The inventors identified the protein through establishing stromal cell lines from the AGM (Aorta-Gonad-Mesonephros) region of a fetal mouse and screening them to see which ones support hematopoiesis, and which type of hematopoietic propensity (eg were they stimulating...
Inventors: Nishikawa; Mitsuo (Gunma, JP)
Assignee: Kirin Pharma Kabushiki Kaisha (Tokyo-To, JP)
Date of First Priority Issue: Friday April 26th, 2002
Compositions for allogeneic cell therapy
Patent Number: 7,435,592This patent covers a composition of activated T cells, either autologous or allogeneic. It is very interesting since the way the claims issued, it covers pretty much any T cell that has been activated by ligation of CD3 and CD28 (the most common way of activating T cell cells). The first independent claim covers a composition of T cells that are contacted with antibodies to CD3...
Inventors: Har-Noy; Michael (Modi'in, IL)
Assignee: Immunovative Therapies, Ltd. (Shoham, IL)
Date of First Priority Issue: Tuesday May 13th, 2003
CXCR4 antagonist treatment of hematopoietic cells
Patent Number: 7,435,718This is a composition of matter patent covering chemical antagonists of the receptor CXCR-4. This receptor binds to stromal derived factor (SDF-1, otherwise known as CXCL12) and maintains the hematopoietic stem cells in the bone marrow. When the receptor is antagonized the hematopoietic stem cells mobilize into circulation. This can be used for...
Inventors: Tudan; Christopher R. (Vancouver, CA), Merzouk; Ahmed (Richmond, CA), Arab; Lakhdar (Vancouver, CA), Saxena; Geeta (Vancouver, CA), Eaves; Connie J. (Vancouver, CA), Cashman; Johanne (Vancouver, CA), Richter, legal representative; Mary A. (Vancouver, CA),
Assignee: Chemokine Therapeutics Corp. (CA); The University of British Columbia (CA)
Date of First Priority Issue: Tuesday May 9th, 2000
Methods for the culture of human embryonic stem cells on human feeder cells
Patent Number: 7,432,104Embryonic stem cells generally require feeder cells to grow on. Traditionally, mouse feeder layers where used, for example in the early work when human embryonic stem cells were patented. The importance of the feeder layer is to provide the right environment for the embryonic stem cells to be capable of proliferating without spontaneously...
Inventors: Mitalipova; Maisam (Athens, GA), Lyons; Ian (Athens, GA)
Assignee: BresGen Inc. (Athens, GA)
Date of First Priority Issue: Tuesday August 6th, 2002
Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions
Patent Number: 7,431,932Activation of innate immune responses is associated in some situations with anti-tumor effects. It is known that viruses activate various cells of the innate immune system such as interferon producing plasmacytoid dendritic cells and natural killer cells. In tumor immunology, it would be...
Inventors: Morris; Donald (Calgary, CA), Thompson; Bradley G. (Calgary, CA), Coffey; Matthew C. (Calgary, CA)
Assignee: Oncolytics Biotech Inc. (Calgary, Alberta, unknown)
Date of First Priority Issue: Wednesday May 3rd, 2000
Unactivated oocytes as cytoplast recipients for nonprimate mammalian and pig nuclear transfer
Patent Number: 7,432,415This is one of Ian Wilmut's many patents on cloning animals (for example 7,321,076, 7,304,204, 6,525,243) This one covers essentially a method of preparing a nonprimate mammalian embryo capable of developing into a live-born nonprimate mammalian animal comprising: (a) culturing a diploid...
Inventors: Campbell; Keith Henry Stockman (Midlothian, GB), Wilmut; Ian (Midlothian, GB)
Assignee: Roslin Institute (Edinburgh, GB)
Date of First Priority Issue: Friday August 30th, 1996
Vasostatin as marrow protectant
Patent Number: 7,432,236Destruction of the bone marrow by chemotherapy or radiotherapy causes significant morbidity and mortality. In fact, hematopoietic toxicity is the main limiting factor of many types of chemotherapeutic agents. Accordingly, it would be interesting if one were to develop an agent or therapeutic approach that could protect the bone marrow, or alternatively, allow bone marrow cells to...
Inventors: Tosato; Giovanna (Bethesda, MD), Pike; Sandra E. (North Bethesda, MD), Yao; Lei (Rockville, MD)
Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services (Rockville, MD)
Date of First Priority Issue: Tuesday October 6th, 1998
Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion
Patent Number: 7,429,383Mobilization of stem cells is big money. For example, the company Anormed was bought by Genzyme for more than half a billion dollars because of its late-phase compound, a CXCR4 antagonist which mobilizes study cells. Why would one be interested in mobilizing stem cells out of the bone marrow? Firstly, this is used instead of drilling holes in the...
Inventors: Scadden; David T. (Weston, MA), Calvi; Laura M. (Rochester, NY), Adams; Gregor (Boston, MA), Kronenberg; Henry (Belmont, MA)
Assignee: The General Hospital Corporation (Boston, MA)
Date of First Priority Issue: Thursday July 25th, 2002
Methods of controlling proliferation and differentiation of stem and progenitor cells
Patent Number: 7,429,489In addition to their usefulness for making new blood cells, hematopoietic stem cells have been demonstrated to induce regeneration of injured liver in cirrhosis patients, possess therapeutic effects in heart failure, and possible are associated with recovery of patients after
Assignee: Gamida Cell Ltd. (Jerusalem, IL); Hadasit Medical Research Services and Development Ltd. (Jerusalem, IL)
Date of First Priority Issue: Tuesday February 17th, 1998
Methods of cancer diagnosis and therapy targeted against a cancer stem line
Patent Number: 7,427,400This patent covers the use of antibodies to Tie-1 and glypican-3 for the treatment of cancer, presumably by selective killing of cancer stem cells. Tie-1 is one of the receptors for angiopoietin, which is activates endothelial cells and is critical in formation of new blood vessels (angiogenesis). Glypican-3 is a heparan sulfate proteoglycan that is anchored to the cell membrane of...
Inventors: Bergstein; Ivan (New York, NY)
Assignee: Stemline
Date of First Priority Issue: Monday December 20th, 1999